上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2021 , Vol. 41 >Issue 5: 622 - 627

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.05.010

论著 · 临床研究

计算机化认知矫正治疗对精神分裂症患者认知功能的影响

  • 胡国芹 ,
  • 杨程青 ,
  • 吕钦谕 ,
  • 赵静 ,
  • 朱明环 ,
  • 易正辉 ,
  • 戴兴海
展开
  • 1.上海市黄浦区精神卫生中心精神科，上海 200011
    2.上海交通大学医学院附属精神卫生中心精神科，上海 200030
    3.上海市浦东新区精神卫生中心精神科，上海 200122
胡国芹（1990—），女，主治医师，硕士；电子信箱：huguoqin1990@126.com。

网络出版日期: 2021-05-27

基金资助

上海市黄浦区科学技术委员会科研计划项目(HKQ201813);上海市黄浦区卫生计生系统专业人才梯队培养计划(2019GG11);上海市卫生健康委员会科研课题(20194Y0406)

收起

Effects of computerized cognitive correction therapy on cognitive function of schizophrenia

  • Guo-qin HU ,
  • Cheng-qing YANG ,
  • Qin-yu Lü ,
  • Jing ZHAO ,
  • Ming-huan ZHU ,
  • Zheng-hui YI ,
  • Xin-hai DAI
Expand
  • 1.Department of Psychiatry, Shanghai Mental Health Center of Huangpu District, Shanghai 200011, China
    2.Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
    3.Department of Psychiatry, Shanghai Mental Health Center of Pudong District, Shanghai 200122, China

Online published: 2021-05-27

Supported by

Shanghai Huangpu District Science and Technology Commission Scientific Research Project(HKQ201813);Shanghai Huangpu District Health and Family Planning Professional Talent Echelon Training Plan(2019GG11);Scientific Research Project of Shanghai Municipal Health Committee(20194Y0406)

Fold

摘要

目的·探讨计算机化认知矫正治疗（computerized cognitive correction therapy，CCRT）辅助疗法对慢性精神分裂症患者认知功能的疗效及对血浆脑源性神经生长因子（brain derived neurotrophic factor，BDNF）和酪氨酸激酶受体B（tyrosine kinase receptors B，TrK-B）表达水平的影响。方法·纳入上海市黄浦区精神卫生中心慢性精神分裂症患者162例，按随机数字表随机分为CCRT组和对照组，每组各81例。对照组以常规抗精神病药物治疗，CCRT组以CCRT联合常规抗精神病药物治疗，治疗时间持续12周。2组在入组时及治疗12周后予神经心理状态评定量表评估认知功能，亲和素-生物素复合酶联免疫吸附试验检测血浆BDNF和TrK-B表达水平。基线期认知功能和血浆BDNF及TrK-B蛋白表达水平2组间比较采用配对样本t检验，2组治疗后与基线期、治疗后2组间认知功能和血浆BDNF及TrK-B蛋白表达水平数据比较使用重复测量方差分析。治疗前后认知功能的改善与蛋白表达改变的相关性用一般线性模型。结果·CCRT组和对照组实际各完成77例。基线期，2组认知功能各维度，BDNF和TrK-B表达水平差异比较无统计学意义；治疗12周后，2组认知功能各维度（P=0.000），BDNF（P=0.007）和TrK-B（P=0.015）表达水平差异有统计学意义；组内比较发现：CCRT组治疗12周与基线期认知功能各维度（P=0.000），BDNF（P=0.002）和TrK-B（P=0.000）表达水平比较差异有统计学意义，对照组治疗12周后认知功能各维度，BDNF和其TrK-B表达水平较基线期比较差异无统计学意义。BDNF蛋白表达水平的改变与词汇学习（r2=1.598，P=0.019）、故事复述（r2=1.495，P=0.038）、数字广度（r2=1.855，P=0.004）、故事回忆（r2=1.459，P=0.047）和注意功能（r2=1.673，P=0.012）改善有显著相关性，TrK-B蛋白表达水平的改变与图画命名的改善有显著相关性（r2=1.582，P=0.034）。结论·CCRT辅助治疗对慢性精神分裂症患者认知功能各维度有显著疗效，且部分认知功能的改善与血浆BDNF和TrK-B表达水平的改变显著相关。

关键词： 精神分裂症; 计算机化认知矫正治疗; BDNF; TrK-B; 认知功能

本文引用格式

胡国芹 , 杨程青 , 吕钦谕 , 赵静 , 朱明环 , 易正辉 , 戴兴海 . 计算机化认知矫正治疗对精神分裂症患者认知功能的影响[J]. 上海交通大学学报（医学版）, 2021 , 41(5) : 622 -627 . DOI: 10.3969/j.issn.1674-8115.2021.05.010

Abstract

Objective

·To explore the effects of computerized cognitive correction therapy (CCRT) on the cognitive function of patients with chronic schizophrenia and the effects on plasma brain-derived nerve growth factor (BDNF) and tyrosine kinase receptors B (TrK-B) .

Methods

·162 patients with chronic schizophrenia from Shanghai Mental Health Center of Huangpu District were randomly divided into CCRT group and control group according to the random number table method. 81 patients in the control group were treated with the conventional antipsychotic drugs, and 81 patients in the CCRT group were given CCRT combined with the conventional antipsychotic treatment. The period of treatments is 12 weeks. The cognitive function by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), detection of plasma BDNF and TrK-B expression levels by avidinbiotincomplex-Enzyme Linked Immune Sorbent Assay (ABC-ELISA) were assessed at the baseline and at the end of the 12th week. Paired sample t-test was applied to compare the cognitive function, plasma BDNF and TrK-B protein expression levels in the baseline between the two groups, and the repeated measurements variance analysis was used to compare the cognitive function and plasma BDNF and TrK-B protein expression levels between the two groups after treatment and change within the group. The correlation between the improvement of cognitive function and the change of protein expression levels used a general linear model.

Results

·The CCRT group and the control group actually completed 77 cases each. At the baseline, there was no statistically significant difference among cognitive function, BDNF and TrK-B between the two groups; after 12 weeks of treatment, cognitive function (P=0.000), BDNF (P=0.007) and TrK-B (P=0.015) expression level was statistically different between the CCRT and the control group; for CCRT group, cognitive function (P=0.000), BDNF (P=0.002) and TrK-B (P=0.000) expression level was significantly different after 12 weeks of treatment compared with the baseline, but not in the control group. The change of BDNF protein expression level is significantly correlated with the improvement of vocabulary learning (r2=1.598, P=0.019), story retelling (r2=1.495, P=0.038), digital breadth (r2=1.855, P=0.004), story recall (r2=1.459, P=0.047) and attention function (r2=1.673,P=0.012). The change of TrK-B protein expression level is significantly correlated with the improvement of picture naming (r2=1.582, P=0.034).

Conclusion

·The use of CCRT in the adjuvant treatment of antipsychotic treatment for schizophrenia patients has a significant effect on cognitive function. The improvement of some cognitive functions are significantly related to the changes in the plasma BDNF and its TrK-B expression levels.

Key words： schizophrenia; computerized cognitive remediation therapy; brain derived neurotrophic factor (BDNF); tyrosine kinase receptor B (TrK-B); cognitive function

参考文献

1 Turetsky BI, Bilker WB, Siegel SJ, et al. Profile of auditory information-processing deficits in schizophrenia[J]. Psychiatry Res, 2009, 165(1/2): 27-37.
2 Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function[J]. Biochem Pharmacol, 2007, 74(8): 1182-1191.
3 Iimori T, Nakajima S, Miyazaki T, et al. Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimer's disease: a systematic review[J]. Prog Neuro - Psychopharmacol Biol Psychiatry, 2019, 88: 31-40.
4 Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review[J]. J Nerv Ment Dis, 2012, 200(10): 832-839.
5 屈英, 肖广荣, 马永珩, 等. 认知矫正治疗对慢性精神分裂症患者临床症状和社会功能的影响[J]. 中国组织工程研究与临床康复, 2007, 11(52): 10553-10556.
6 谭淑平, 邹义壮, 王健, 等. 认知矫正治疗慢性精神分裂症患者认知功能缺陷的随机对照研究[J]. 中华精神科杂志, 2010, 43(3): 140-145.
7 Tan SP, Liu DT. A review of the Chinese literature on cognitive remediation in psychosis[J]. Asian J Psychiatry, 2016, 22: 129-134.
8 Fernandez-Gonzalo S, Turon M, Jodar M, et al. A new computerized cognitive and social cognition training specifically designed for patients with schizophrenia/schizoaffective disorder in early stages of illness: a pilot study[J]. Psychiatry Res, 2015, 228(3): 501-509.
9 Hogarty GE, Flesher S, Ulrich R, et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior[J]. Arch Gen Psychiatry, 2004, 61(9): 866-876.
10 Dickinson D, Tenhula W, Morris S, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia[J]. Am J Psychiatry, 2010, 167(2): 170-180.
11 Ibrahim I, Tobar S, Fathi W, et al. Randomized controlled trial of adjunctive Valproate for cognitive remediation in early course schizophrenia[J]. J Psychiatr Res, 2019, 118: 66-72.
12 王健, 邹义壮, 崔界峰, 等. 韦氏成人智力量表第四版中文版的信度和结构效度[J]. 中国心理卫生杂志, 2013, 27(9): 692-697.
13 Morice R, Delahunty A. Frontal/executive impairments in schizophrenia[J]. Schizophr Bull, 1996, 22(1): 125-137.
14 Randolph C, Tierney MC, Mohr E, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity[J]. J Clin Exp Neuropsychol, 1998, 20(3): 310-319.
15 张保华, 谭云龙, 张五芳, 等. 重复性成套神经心理状态测验的信度、效度分析[J]. 中国心理卫生杂志, 2008, 22(12): 865-869.
16 Wilk CM, Gold JM, Bartko JJ, et al. Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia[J]. Am J Psychiatry, 2002, 159(5): 838-844.
17 刘燕, 沈辉, 邓红玉, 等. 精神分裂症认知矫正治疗新进展[J]. 神经疾病与精神卫生, 2018, 18(7): 515-519.
18 Reser MP, Slikboer R, Rossell SL. A systematic review of factors that influence the efficacy of cognitive remediation therapy in schizophrenia[J]. Aust N Z J Psychiatry, 2019, 53(7): 624-641.
19 Gomar JJ, Valls E, Radua J, et al. A multisite, randomized controlled clinical trial of computerized cognitive remediation therapy for schizophrenia[J]. Schizophr Bull, 2015, 41(6):1387-1396.
20 Ramsay IS, MacDonald AW 3rd. Brain correlates of cognitive remediation in schizophrenia: activation likelihood analysis shows preliminary evidence of neural target engagement[J]. Schizophr Bull, 2015, 41(6): 1276-1284.
21 Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms[J]. Trends Cogn Sci, 2012, 16(1): 27-34.
22 Eisenberg DP, Berman KF. Executive function, neural circuitry, and genetic mechanisms in schizophrenia[J]. Neuropsychopharmacology, 2010, 35(1): 258-277.
23 Habtemariam S. The brain-derived neurotrophic factor in neuronal plasticity and neuroregeneration: new pharmacological concepts for old and new drugs[J]. Neural Regen Res, 2018, 13(6): 983-984.
24 Wang Q, Shao F, Wang WW. Region-dependent alterations in cognitive function and ERK1/2 signaling in the PFC in rats after social defeat stress[J]. Neural Plast, 2018, 2018: 9870985.
25 Pillai A, Kale A, Joshi S, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology[J]. Int J Neuropsychopharmacol, 2010, 13(4): 535-539.
26 Klein AB, Williamson R, Santini MA, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species[J]. Int J Neuropsychopharmacol, 2011, 14(3): 347-353.
Options
文章导航

/

〈 〉